| Typicality: | 0.331 |
| Saliency: | 0.396 |
| in preclinical models | 5 | location |
| on several real-world applications | 5 | location |
| in early phase clinical trials | 3 | location |
| approach → shown → promising results | 16 |
| approach → show → promising results | 8 |
| approach → yield → promising results | 5 |
| approach → provide → promising results | 3 |
| approach → demonstrate → promising results | 3 |
| negative | neutral | positive |
| 0.019 | 0.120 | 0.861 |
| Raw frequency | 35 |
| Normalized frequency | 0.396 |
| Modifier score | 0.500 |
| Perplexity | 57.829 |